Antiviral Research Briefs: AbbVie/Enanta, Argos
Executive Summary
Research highlights from the Conference on Retroviruses and Opportunistic Infections, including the potential for immunotherapy in HIV and continued signs of strength for Enanta/AbbVie’s coming HCV combo.